2023 World Conference on Lung Cancer (Posters)-EP12.02. The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan

EP12.02. The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan - PDF(Slides)

Back to course

Pdf Summary

This real-world study evaluated the effectiveness and safety of lorlatinib, a third-generation tyrosine kinase inhibitor, in the treatment of previously treated non-small cell lung cancer (NSCLC) patients with ROS1 rearrangements. The study included 10 patients who received lorlatinib after the failure of previous treatment options. The results showed that lorlatinib demonstrated durable treatment effectiveness, with an overall response rate of 33% and a disease control rate of 89%. The intra-cranial response rate was 22%, and the intra-cranial disease control rate was 89%. During the follow-up period, four patients experienced disease progression, while six patients continued to receive lorlatinib treatment. The median progression-free survival had not been reached at the time of the study. All patients were still alive at the end of the study. The safety profile of lorlatinib was consistent with previous clinical studies and real-world evidence studies, with mild to moderate adverse events observed, including hyperlipidemia, depression, edema, weight gain, and peripheral sensory neuropathy. However, cognitive effects were not captured in this study due to its retrospective nature. The study concludes that lorlatinib shows promise as an effective treatment option for previously treated NSCLC patients with ROS1 rearrangements. However, further research is needed with larger patient populations and longer study periods to fully investigate the efficacy and effectiveness of lorlatinib in this patient population.

Asset Subtitle

Xuet Yit Chen

Meta Tag

Speaker Xuet Yit Chen

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

lorlatinib

tyrosine kinase inhibitor

non-small cell lung cancer

NSCLC

ROS1 rearrangements

treatment effectiveness

response rate

disease control rate

progression-free survival

safety profile